Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Jan
13
Today In Oncology
Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive mCRPC
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
Do GLP-1 RAs Reduce the Risk of Developing Colorectal Cancer More Than Aspirin
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo